Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 27 04:00PM ET
128.05
Dollar change
-1.36
Percentage change
-1.05
%
Index- P/E47.40 EPS (ttm)2.70 Insider Own0.00% Shs Outstand3.38B Perf Week-1.77%
Market Cap433.25B Forward P/E31.13 EPS next Y4.11 Insider Trans- Shs Float3.38B Perf Month4.76%
Income12.14B PEG16.93 EPS next Q0.77 Inst Own9.15% Short Float0.12% Perf Quarter24.71%
Sales33.70B P/S12.86 EPS this Y25.20% Inst Trans-2.70% Short Ratio0.80 Perf Half Y39.50%
Book/sh4.67 P/B27.44 EPS next Y21.09% ROA29.90% Short Interest4.11M Perf Year65.55%
Cash/sh1.32 P/C96.72 EPS next 5Y2.80% ROE87.44% 52W Range75.56 - 138.28 Perf YTD23.78%
Dividend Est.1.67 (1.30%) P/FCF35.93 EPS past 5Y16.48% ROI64.47% 52W High-7.40% Beta0.41
Dividend TTM1.37 (1.07%) Quick Ratio0.64 Sales past 5Y14.25% Gross Margin84.60% 52W Low69.47% ATR (14)2.91
Dividend Ex-DateMar 22, 2024 Current Ratio0.82 EPS Y/Y TTM56.16% Oper. Margin44.12% RSI (14)51.65 Volatility1.55% 1.87%
Employees63370 Debt/Eq0.25 Sales Y/Y TTM34.77% Profit Margin36.04% Recom2.03 Target Price132.11
Option/ShortYes / Yes LT Debt/Eq0.19 EPS Q/Q71.63% Payout36.04% Rel Volume0.77 Prev Close129.41
Sales Surprise4.87% EPS Surprise6.77% Sales Q/Q44.01% EarningsJan 31 BMO Avg Volume5.16M Price128.05
SMA20-1.13% SMA505.83% SMA20028.19% Trades Volume3,941,235 Change-1.05%
Date Action Analyst Rating Change Price Target Change
Jan-23-24Initiated Morgan Stanley Overweight $120
Jan-16-24Resumed UBS Neutral
Dec-01-23Initiated Cantor Fitzgerald Overweight $120
Oct-02-23Initiated Argus Buy $110
Jul-14-23Initiated HSBC Securities Buy
Jul-15-22Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-28-22Downgrade UBS Neutral → Sell
Jun-27-22Upgrade Exane BNP Paribas Underperform → Neutral
Jun-07-22Upgrade JP Morgan Neutral → Overweight
May-31-22Upgrade Guggenheim Neutral → Buy
Mar-27-24 06:29PM
05:47PM
Mar-26-24 01:02PM
12:59PM
12:13PM
11:58AM Loading…
11:58AM
11:15AM
11:13AM
10:56AM
10:35AM
05:51AM
05:10AM
Mar-25-24 08:44PM
05:50PM
01:06PM
12:22PM Loading…
12:22PM
10:43AM
10:00AM
09:49AM
09:07AM
08:54AM
08:42AM
07:58AM
07:21AM
07:13AM
06:25AM
06:17AM
05:59AM
03:51AM
Mar-24-24 10:58AM
09:15AM Loading…
09:15AM
Mar-22-24 04:42PM
12:25PM
11:53AM
10:30AM
07:42AM
07:15AM
07:08AM
05:37AM
Mar-21-24 04:44PM
04:23PM
03:35PM
02:32PM
02:18PM
01:12PM
12:31PM
11:55AM
11:50AM
10:59AM
10:25AM
10:15AM
08:53AM
05:58AM
Mar-20-24 05:51PM
11:20AM
08:30AM
08:00AM
Mar-19-24 10:00AM
07:30AM
05:50AM
03:00AM
Mar-18-24 05:50PM
10:18AM
10:05AM
09:30AM
Mar-17-24 02:28PM
09:46AM
09:00AM
08:50AM
05:00AM
Mar-16-24 05:00AM
Mar-15-24 01:38PM
11:16AM
10:18AM
10:15AM
09:50AM
07:46AM
05:50AM
Mar-14-24 09:38AM
05:15AM
Mar-13-24 12:40PM
05:03AM
01:00AM
Mar-12-24 08:31PM
04:53PM
03:13PM
12:00PM
12:00PM
11:34AM
10:28AM
09:30AM
08:53AM
07:45AM
05:00AM
Mar-11-24 05:50PM
12:44PM
10:33AM
09:45AM
08:46AM
07:23AM
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsvaerd, Denmark.